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Abstract
Background: Severe anemia due to Plasmodium falciparum malaria is a major cause of mortality among young children
in western Kenya. The factors that lead to the age-specific incidence of this anemia are unknown. Previous studies have
shown an age-related expression of red cell complement regulatory proteins, which protect erythrocytes from
autologous complement attack and destruction. Our primary objective was to determine whether in a malaria-endemic
area red cells with low levels of complement regulatory proteins are at increased risk for complement (C3b) deposition
in vivo. Secondarily, we studied the relationship between red cell complement regulatory protein levels and hemoglobin
levels.
Methods: Three hundred and forty-two life-long residents of a malaria-holoendemic region of western Kenya were
enrolled in a cross-sectional study and stratified by age. We measured red cell C3b, CR1, CD55, and immune complex
binding capacity by flow cytometry. Individuals who were positive for malaria were treated and blood was collected when
they were free of parasitemia. Analysis of variance was used to identify independent variables associated with the %C3b-
positive red cells and the hemoglobin level.
Results: Individuals between the ages of 6 and 36 months had the lowest red cell CR1, highest %C3b-positive red cells,
and highest parasite density. Malaria prevalence also reached its peak within this age group. Among children ≤ 24 months
of age the %C3b-positive red cells was usually higher in individuals who were treated for malaria than in uninfected
individuals with similarly low red cell CR1 and CD55. The variables that most strongly influenced the %C3b-positive red
cells were age, malaria status, and red cell CD55 level. Although it did not reach statistical significance, red cell CR1 was
more important than red cell CD55 among individuals treated for malaria. The variables that most strongly influenced
the hemoglobin level were age, the %C3b-positive red cells, red cell CR1, and red cell CD55.
Conclusion: Increasing malaria prevalence among children >6 to ≤ 36 months of age in western Kenya, together with
low red cell CR1 and CD55 levels, results in increased C3b deposition on red cells and low hemoglobin. The strong
contribution of age to C3b deposition suggests that there are still additional unidentified age-related factors that increase
the susceptibility of red cells to C3b deposition and destruction.
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Background
Plasmodium falciparum malaria is responsible for 1 to 2
million deaths per year, with most in sub-Saharan Africa
[1]. One unexplained but consistent feature of the epide-
miology of clinical malaria is the age distribution of syn-
dromes of severe disease. Severe anemia is most common
in areas of intense transmission of P. falciparum and tends
to occur in children <3 years of age, whereas cerebral
malaria occurs in areas where the annual inoculation rate
is low, and it occurs in older children and adults [2-5].
The pathogenesis of severe anemia in malaria is complex.
However, a number of observations suggest that the
destruction of uninfected red cells is a significant contrib-
utor to, if not the major cause of, this anemia: uninfected
red cells have a decreased life span in patients with P. fal-
ciparum [6] and the hematocrit can continue to decrease
for days following treatment [7]. Further, the fact that the
life span of erythrocytes is 120 days suggests that bone
marrow dysfunction would have to be very prolonged to
make a significant contribution to this anemia. A mathe-
matical model of severe malarial anemia has revealed that
with each lysed infected erythrocyte a further 8.5 unin-
fected erythrocytes are destroyed [8]. These observations
suggest that destruction of uninfected red cells takes place
during malaria infection. Complement activation and its
deposition on red cells are prime suspects in this process.
Complement is activated during malaria infection [9,10]
and C3d and IgG, molecules that are implicated in the
removal of senescent red cells via erythrophagocytosis
[11], have been detected on red cells of children with
severe malaria [12,13].
In order to understand the nature of the susceptibility of
red cells to complement activation during malaria infec-
tion we have investigated the expression of red cell com-
plement regulatory proteins in persons living in a malaria-
endemic area. Complement receptor 1 (CR1, CD35) is a
200 kDa protein that is found on red cells and most leu-
kocytes [14]. It also accelerates the decay of C3 and C5
convertases, protein complexes that catalyze the cleavage
of C3 and C5 into C3b and C5b respectively [15]. Red
cells are able to bind C3b-bearing immune complexes
(ICs) via CR1 and carry them to the liver and spleen where
they are removed from circulation [16,17]. Therefore, CR1
prevents the deposition of C3b on cell surfaces and has a
critical role in the removal of ICs from circulation.
The other red cell complement regulatory protein that we
have studied is decay accelerating factor (DAF, CD55)
[18]. It is a 70 kDa protein linked to the cell membrane via
glycosyl-phosphatidyl-inositol (GPI). CD55 catalyzes the
degradation of C3 convertases and also promotes the
inactivation of C3b [19,20]. Deficiency in membrane DAF
and CD59, a third red cell complement regulator, leads to
paroxysmal nocturnal hemoglobinuria, a condition char-
acterized by massive hemolysis due to complement acti-
vation on red cells. Consequently, red cell complement
regulatory proteins may play an important role in protect-
ing red cells from complement-mediated destruction as a
result of IC formation and complement activation that
occur during malaria infection [9,21]. Consistent with
this hypothesis, we have found that red cells of children
with  P. falciparum infection and severe anemia have
acquired deficiencies in CR1 and CD55, and increased
C3b deposition [13,22]. Excessive C3b deposition on red
cells during malaria infection as a result of deficiency in
red cell complement regulatory proteins may result in
increased destruction of red cells by phagocytosis and
severe anemia [15].
To understand the age predilection of severe anemia dur-
ing P. falciparum infection, we have studied the relation-
ship between red cell CR1 and CD55 and age. Our studies
suggest that the expression of red cell CR1 and CD55 are
age-dependent, decreasing from birth to a nadir some-
where between 1 and 2 years of age and rising thereafter
[23]. This pattern has been observed in populations of
diverse ethnic origin and is independent of malaria infec-
tion. We have proposed that the changes in the expression
of red cell complement regulatory proteins with age may
influence the susceptibility of red cells to complement-
mediated damage and, by extension, the age predilection
for severe anemia during malaria infection [24]. To test
whether the susceptibility of red cells to C3b deposition is
influenced by the age-related changes in complement reg-
ulatory proteins we carried out a cross-sectional study of
individuals in a malaria-holoendemic region of western
Kenya, measured their red cell CR1, CD55, and IC binding
capacity, and determined the %C3b-positive red cells.
Methods
Study design and population
The study was cross-sectional in design and was approved
by the Walter Reed Army Institute of Research Human Use
Research Committee and by the National Ethical Review
Committee, Nairobi, Kenya. It was carried out from Octo-
ber through December 2004 in Kombewa Division, an
area off the shores of Lake Victoria within Kisumu District.
Malaria is holoendemic in this region, occurring through-
out the year with peak seasons during the long rains
(March through August) and during the short rains (Octo-
ber through December) [25]. The area is divided into four
sub-Divisions and 12 political locations with approxi-
mately 62,000 inhabitants. The majority of the inhabit-
ants are of the Luo ethnic group and dedicate themselves
to subsistence farming and fishing.
Enrollment was stratified into nine age groups selected
based on the age distribution of children with severe ane-
mia (Hgb ≤ 5.0 g/dl) and P. falciparum malaria from Kis-
umu District, western Kenya, who participated in ourBMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
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studies from 1998 to 2001 [13,26,27]: 0 to ≤ 6 months, >6
to ≤ 12 months, >12 to ≤ 18 months, >18 to ≤ 24 months,
>24 to ≤ 36 months, >36 to ≤ 72 months, >72 to ≤ 144
months, >144 to ≤ 288 months, and >288 to ≤ 540
months. Since we had no previous data on the levels of
C3b deposition on red cells, enrollment targets for each
group were set to maximize the probability of detecting
significant differences between the >6 to ≤ 12 month
group, where we had seen the lowest level of CR1 in a pre-
vious study [28], and other groups. The inclusion criterion
was any person male or female of age 45 years or younger
who was a life-long resident of the study area. As many
conditions including malaria [13], HIV infection [29],
and others [30,31] can alter the level of red cell comple-
ment regulatory proteins, the following exclusion criteria
were established: 1) evidence on clinical grounds of mal-
nutrition manifested by marasmus or kwashiorkor; 2)
immunocompromised status manifested by weight loss,
thrush, or diffuse adenopathy; 3) severe anemia (Hgb ≤
5.0 g/dl); 4) bacterial infection (for example, pneumo-
nia); 5) malignancy; and 6) blood transfusion within 3
months preceding the study.
A preliminary census was carried out within selected vil-
lages to identify potential participants. All individuals
who met the entry criteria were invited to participate. On
the days of recruitment individuals or parents with chil-
dren self-reported to the clinic for enrollment in the study.
Informed consent was obtained prior to any procedures.
Individuals underwent a standard medical evaluation.
Date of birth was confirmed by national registration card,
baptismal certificate, or birth certificate. During the initial
screening, blood obtained by finger prick was used to pre-
pare thick and thin Giemsa-stained blood smears. If an
individual was positive for malaria, he or she was treated
with artemether/lumefantrine [32] and asked to return 2
weeks later for re-evaluation. Individuals who were febrile
(oral or axillary temperature >37.5°C) without malaria
were evaluated and treated for any minor illness identified
and asked to return 2 weeks later. Individuals who
returned for re-evaluation were screened for malaria
again. If found to be malaria positive or febrile at this sec-
ond screen, they were again evaluated, treated, and asked
to come back 2 weeks later.
Blood samples and smears
Malaria smears were read by trained and certified micro-
scopists. All smears were read in duplicate by independent
microscopists who were unaware of the status of the par-
ticipants. Discrepancies were settled by a third independ-
ent microscopist. A smear required a minimum of 200
high power fields scanned prior to being considered neg-
ative. Once an individual was deemed well and asympto-
matic, a 2.5 ml ethylenediaminetetraacetic acid (EDTA)-
anticoagulated sample of venous blood was obtained. An
aliquot was used for complete blood count determination
using an automated hematology analyzer (Coulter,
Hialeah, FL). The remaining sample was centrifuged and
the plasma removed. The red blood cell pellet was then
cryopreserved until used [33].
Flow cytometric measurement of CR1 and CD55
Erythrocyte CR1 and CD55 levels were determined using
frozen samples. In preliminary experiments, we observed
no difference in the level of red cell complement regula-
tory proteins between fresh and frozen samples. All pri-
mary antibodies were titered to saturation. 10 μl of
thawed erythrocyte pellet was washed twice in 1 ml of
Alsever's buffer and resuspended in the same volume of
buffer. Unless otherwise stated, all procedures were as pre-
viously described [34]. The following primary antibodies
were used in dilutions of 1:20: anti-CR1 clone E11, anti-
CD55 clone IA10, and isotype controls for each (Becton-
Dickinson, Belgium). A secondary fluorescein isothiocy-
anate (FITC)-conjugated goat anti-mouse IgG (Becton-
Dickinson, San Diego, CA) was used at a dilution of 1:50.
Flow cytometry was carried out using a FACScan flow
cytometer (Becton-Dickinson). Analysis was done using
FCS Express v2.5 (De Novo Software, Los Angeles, CA).
Red cells were gated on the basis of their forward and side
scatter characteristics using logarithmic amplification. The
median fluorescence intensity (MFI) of each sample was
measured using logarithmic amplification. The MFI val-
ues for CR1 and CD55 were normalized to the mean of
the MFI of the red cell standard using the formula
CorrMFIs = MFIs × MFIcmean/MFIc,
where 'CorrMFIs' and 'MFIs' are the corrected and uncor-
rected sample MFI respectively, 'MFIcmean' is the mean of
all the MFI values of the standard control, and 'MFIc' is the
mean of the control obtained in parallel with the sample.
The number of molecules of CR1 per red cell was derived
from a fluorescence standard curve created using cells
with known CR1 numbers. Red cell anti-CD55 antibody
binding capacities were derived from a standard curve cre-
ated using beads of known antibody binding capacity
(Bangs Lab, Fishers, IN) [35].
Preparation of ICs
50  μl of 49 mg/ml rabbit anti-BSA (Sigma-Adrich, St.
Louis, MO) and 3 μl of 5 mg/ml BSA-FITC (Accurate
Chemical and Scientific Corp., Westbury, NY) were added
to 950 μl of RPMI1640 (Sigma-Aldrich). This combina-
tion was noted to be the point of equivalence in prelimi-
nary experiments. The mixture was incubated at 37°C for
1 hr and overnight at 4°C. The next day, the IC prepara-
tion of soluble and insoluble IC was aliquoted and stored
at -20°C.BMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
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Measurement of C3b on red cells
All centrifugation steps were at × 500 g for 5 min. Rabbit
polyclonal anti-C3a (negative control antibody) and anti-
C3b (Accurate) were pre-adsorbed ×3 by adding a 1:50
dilution of antibody in phosphate buffered saline (PBS)
pH 7.4 to an equal volume of packed pre-washed erythro-
cytes from the normal standard control. The cells were
incubated for 1 hr at 37°C with constant rocking followed
by centrifugation. The pre-adsorbed antibody was frozen
at -20°C in single-use aliquots. 100 μl of pre-washed
freshly thawed erythrocytes at 1% hematocrit in Alsever's
buffer was added to wells of a 96-well plate and resus-
pended in 50 μl of pre-adsorbed rabbit anti-C3b, anti-
C3a, or in PBS (unstained control), and incubated for 10
min at 37°C. After two washes in PBS, the cells were resus-
pended in 1:50 anti-rabbit PE (Sigma-Aldrich) for 30 min
at room temperature, washed twice, and resuspended
again in PBS. Acquisition was carried out as above. The
%C3b-positive cells were calculated by Overton subtrac-
tion [36] of the baseline C3a histogram from the baseline
C3b histogram.
Measurement of IC binding capacity
For IC opsonization, 5 μl of stock IC or RPMI 1640
(unstained control) was incubated in a total volume of
100 μl containing 30% AB+ serum in wells of a 96-well
plate. For a negative control, a separate set of wells con-
tained IC plus 10 mM EDTA. Following incubation at
37°C for 30 min with constant rocking motion, 100 μl of
1% hematocrit suspension of freshly thawed red cells
from each study participant or from a standard apara-
sitemic control in RPMI 1640 was added to each of the
wells of the above 96-well plate. This was followed by fur-
ther incubation for 30 min at 37°C. The erythrocytes were
then washed twice in 200 μl of ice-cold RPMI 1640, resus-
pended in PBS containing 1% paraformaldehyde, and
stored at 4°C until acquisition. After gating, the erythro-
cyte FITC fluorescence was measured using logarithmic
amplification and the positive cutoff was set using the
unstained cells. The percent of positive red cells (IC bind-
ing capacity) was calculated based on this cutoff. To con-
trol for day-to-day variation, the IC binding capacity was
normalized to the mean IC binding capacity of the red cell
standard used throughout using a formula similar to the
one used for correction of CR1 and CD55 (above).
Statistical analysis
Statistical analysis was carried out using SPSS v11.5 (SPSS
Inc., Chicago, IL). The flow cytometry and parasite density
data are presented graphically for each age group as box
plots, where the box represents the boundaries between
the 25th and 75th percentile, the line through the box rep-
resents the median, the whiskers the 10th and 90th percen-
tile limits, and the dots are the outliers. Analysis of
variance (ANOVA) was used to detect differences across
age groups adjusting for factors and covariates as indi-
cated in the figure legends. P values were adjusted for mul-
tiple comparisons using the Sidak correction. The
independent samples t-test was used for comparisons of
normal continuous data between two groups. The chi-
square test was used to compare proportions across
groups. The general linear model procedure was used to
carry out univariate ANOVA and analysis of covariance
(ANCOVA) to identify independent variables associated
with the %C3b-positive red cells and the hemoglobin
level. Age groups, red cell CR1, red cell CD55, parasite
density, malaria status, and IC binding capacity were the
independent predictor variables included in the models.
%C3b-positive red cells were also used as an independent
variable for the hemoglobin level. Categorical variables
were transformed into dummy variables and the B coeffi-
cient for the last group set to '0' for reference. All tests were
two-sided with α ≤ 0.05.
Results
Demographic and clinical characteristics of the study 
population
Four hundred and two potential participants or parents of
children who met the inclusion criterion signed the con-
sent form and were screened. Of these, 344 met none of
the exclusion criteria, attended the screening sessions, and
agreed to provide blood samples (Table 1). Blood samples
could not be drawn in sufficient quantities from two indi-
viduals, making the final number of samples available for
the study 342. All individuals who were parasitemic were
treated for malaria and in most cases the blood sample
was collected 2 weeks later. Table 2 summarizes the
demographic characteristics of the enrolled participants
that contributed samples. We observed no difference in
the proportion of locations or villages represented across
the groups (data not shown).
Red cell CR1, CD55, and IC binding capacity
The nadir of hemoglobin level occurred in the >12 to ≤ 18
month group (Figure 1a). For multiple comparison test-
ing we collapsed the age groups for age >6 to ≤ 36 months,
which seemed to form a homogeneous subset in most
analyses (data not shown), to reduce the number of com-
parisons and compared all other groups to this new group
(Figure 1). The changes in hemoglobin level across groups
were highly statistically significant. Although overall
unadjusted changes in CR1, CD55, and IC binding capac-
ity across age groups were statistically significant, only a
limited number of comparisons were statistically signifi-
cant after adjustment for malaria status and parasite den-
sity (Figure 1). Nonetheless, these findings confirm our
previous results [37]. In the present study, children of
between 6 and 36 months of age had the lowest red cell
CR1 (Figure 1b) whereas children between 24 and 36
months of age had the lowest red cell CD55 (Figure 1c).BMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
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The red cell IC binding capacity showed a pattern similar
to that of CR1 but with a less marked rise in adulthood
(Figure 1d).
Red cell C3b, malaria prevalence, and parasite density
The %C3b-positive red cells increased from birth, peaked
between 12 and 24 months of age and then decreased into
adulthood (Figure 2a). Significant statistical differences in
%C3b-positive red cells were observed when comparing
children >6 to ≤ 36 months with other age groups (Figure
1a). The prevalence of P. falciparum malaria and the para-
site density both rose and peaked within this age group.
However, the prevalence of P. falciparum malaria (Figure
2b) and the distribution of parasite densities among
malaria-positive (heretofore referred to as malaria-
treated) individuals (Figure 2c) were discordant. The par-
asite prevalence increased from birth to 18 months, and
peaked between 18 and 24 months, remaining high up to
age 12 years, and decreasing thereafter (Figure 2b). A sim-
ilar age distribution of parasite prevalence was observed
when all the individuals screened were included, except
that the prevalence was higher across all groups (data not
shown). On the other hand, the parasite densities among
malaria-treated individuals peaked between 12 and 18
months of age and were highest between 6 and 36 months
(Figure 2c).
When participants were subcategorized according to the
presence or absence of P. falciparum at enrollment (Figure
3) we observed that there was an age-dependent distribu-
tion of %C3b-positive red cells both in malaria-treated
and aparasitemic individuals that was more marked in the
former (Figure 3a). In addition, malaria-treated children
of age ≤ 24 months had a greater proportion of C3b-pos-
itive red cells than their aparasitemic counterparts,
although the difference did not reach statistical signifi-
cance in the >12 to ≤ 18 month group. It was surprising to
see that malaria-treated children of age ≤ 6 months (n = 6)
had a high level of %C3b-positive red cells, but this was
explained by relatively low red cell CR1 in these individu-
als. With few exceptions there were no significant differ-
ences in levels of CR1, CD55, and hemoglobin between
malaria-treated and aparasitemic volunteers (Figures 3b
to 3d).
Analysis of variance to detect associations
We carried out analysis of variance to identify the factors
most strongly associated with the %C3b-positive red cells
Table 1: Disposition of participants
Enrolled (N) Deferred to Next Screen Excluded
N Reason for Deferral N Reason for Exclusion
Screen 1 190 194 190- positive blood smear, 18 3- refused blood draw
4- non-malaria fever 12- malnourished or immunocompromised
2- pneumonia
1- severe anemia
Screen 2 151 10 All positive smear 33 1- age cohort full
32- no shows
Screen 3 3 0 7 4- no shows,
3- age cohort full
Total 344* 58
*Two individuals excluded due to insufficient sample.
Table 2: Population demographics
Age Groups (Months) Total N No. Female (%) Median Age in Months (Range)
0 to ≤ 6 30 17 (56.7) 2.6 (0.4 to 0.6)
>6 to ≤ 12 60 29 (48.3) 10.9 (6.1 to 12.0)
>12 to ≤ 18 34 13 (38.2) 14.2 (12.1 to 17.5)
>18 to ≤ 24 27 14 (51.9) 21.3 (18.3 to 23.7)
>24 to ≤ 36 31 14 (45.2) 28.6 (24.2 to 36.0)
>36 to ≤ 72 42 22 (52.4) 42.7 (36.8 to 70.5)
>72 to ≤ 144 39 17 (43.6) 99.2 (73.1 to 143.9)
>144 to ≤ 288 24 12 (50.0) 248.9 (145.1 to 288.0)
>288 to ≤ 540 55 31 (56.4) 393.4 (290.7 to 540.0)
Total 342 169 (49.4) 29.7 (0.4 to 540.0)BMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
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and with the hemoglobin level in all the samples and in
the subgroups of aparasitemic and malaria-treated partic-
ipants (Tables 3 and 4). For the C3b analysis, terms for age
groups, red cell CR1, IC binding capacity, malaria status
(included for all the samples only), parasite density at
enrollment, and red cell CD55 were used as independent
variables. There were no significant interactions between
CR1 and CD55, between CR1 or CD55 and age, or para-
site density and other factors. The unadjusted and
adjusted (all variables entered) results are presented in
Table 3. Age was the most influential factor in all the anal-
yses. Inclusion in the age group >6 to ≤ 36 months always
had the strongest positive effect on C3b deposition, as
seen from its larger correlation coefficient and positive B
coefficient. In the unadjusted analysis, CR1 and CD55
were more influential than malaria status, parasite den-
sity, or IC binding capacity both in the global and in the
subgroup analyses. After adjustment for all the confound-
ing effects, malaria status and CD55 made the most signif-
icant contribution after age when all the samples were
included, while CR1 showed a trend towards significance
(P  = 0.07). For the adjusted analysis of samples from
Age-related changes in hemoglobin concentration, red cell CR1, CD55, and IC binding capacity Figure 1
Age-related changes in hemoglobin concentration, red cell CR1, CD55, and IC binding capacity. For multiple 
comparison testing all groups were compared with the group formed by collapsing the groups ranging in age from >6 to ≤ 36 
months (bracket). P values were adjusted using the Sidak correction for multiple comparisons. * = 0.01 <P ≤ 0.05, ** = P < 0.01. 
a. Hemoglobin level. Unadjusted ANOVA for differences across groups P = 9.6 × 10-38. After adjustment for red cell CR1, red 
cell CD55, %C3b-positive red cells, malaria status, and parasite density, significant differences were found as indicated. b. Red 
cell CR1. Unadjusted ANOVA for differences across groups P = 1.5 × 10-10. After adjustment for malaria status and parasite 
density differences were found as indicated. c. Red cell CD55. Unadjusted ANOVA for differences across groups P = 6.1 × 10-
6. After adjustment for malaria status and parasite density significant differences were found as indicated. ABC = Antibody bind-
ing capacity. d. binding capacity. Unadjusted ANOVA for differences across groups P = 0.004. After adjustment for malaria sta-
tus and parasite density significant differences were found as indicated.
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malaria-treated individuals, age was the only statistically
significant factor followed by CR1, which showed a trend
towards significance (P = 0.09). Of interest, parasite den-
sity was not important in either analysis. Lastly, in the
adjusted analysis of samples from malaria-negative indi-
viduals, CD55 and IC binding capacity made the strongest
contribution after age.
Changes in %C3b-positive red cells, parasite prevalence, and parasite density with age Figure 2
Changes in %C3b-positive red cells, parasite prevalence, and parasite density with age. a.%C3b-positive red cells 
by age. For multiple comparison testing age groups >6 to ≤ 36 months were collapsed into one. P values were obtained by one-
way analysis of variance adjusting for red cell CR1, red cell CD55, IC binding capacity, malaria status, and parasite density.* = 
0.01 <P ≤ 0.05, ** = P < 0.01. Sidak correction for multiple comparisons was used. b. Prevalence of parasitemia by age group. c. 
Parasite density among malaria-positive individuals by age group. Parasite densities were Log10-transformed due to unequal var-
iances between groups. Groups from >6 to ≤ 36 months of age were collapsed into one group and unadjusted comparisons 
between it and all other groups group were carried out. Sidak correction for multiple comparisons was used; ** = P < 0.01.
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For the analysis of factors associated with the hemoglobin
level (Table 4), once again age made the strongest contri-
bution both in the unadjusted and adjusted analyses. Of
all the age groups, the >6 to ≤ 36 months group also had
the strongest negative effect on the hemoglobin level. In
the unadjusted analysis, %C3b-positive red cells, parasite
density, and red cell CR1 always exerted a significant
influence on hemoglobin level. The IC binding capacity
made significant contributions in the unadjusted analysis
of all the samples and the samples from malaria negative
individuals. In the adjusted analysis, in addition to age,
red cell CR1, %C3b-positive red cells, and CD55 made a
significant contribution to the hemoglobin level using all
the samples and the samples from individuals who were
negative for malaria. Interestingly, CD55 among apara-
sitemic individuals had a negative, although very small, B
coefficient, meaning that in this group CD55 seemed to
be associated with declining hemoglobin level. For the
analysis that included samples from malaria-treated indi-
viduals, red cell CR1 and age exerted the greatest influence
on the hemoglobin level.
Changes in %C3b-positive red cells, CR1, CD55, and hemoglobin according to malaria status Figure 3
Changes in %C3b-positive red cells, CR1, CD55, and hemoglobin according to malaria status. a. %C3b-positive 
red cells. Unadjusted ANOVA for the difference in %C3b-positive red cells across groups P(malaria-treated) = 2.5 × 10-11, 
P(aparasitemic) = 1.2 × 10-7. Independent samples t-test for the comparison between malaria-treated and aparasitemic individ-
uals for the indicated age groups, *P = 0.04, †P = 2.8 × 10-4, ‡P = 0.09, ¶P = 0.03. b. Red cell CD55. Unadjusted ANOVA for the 
difference in CD55 across groups, P(malaria-treated) = 0.01 and P(aparasitemic) = 0.05. ABC = Antibody binding capacity. c. 
Red cell CR1. Unadjusted ANOVA for the difference in CR1 across groups, P(malaria-treated) = 0.02 and P(aparasitemic) = 1.9 
× 10-6. Independent samples t-test for the comparison between malaria-treated and aparasitemic individuals for the indicated 
age groups, *P = 0.01, †P = 0.58, ‡P = 0.09. d. Hemoglobin level. Unadjusted ANOVA for the difference in Hgb level across 
groups, P(malaria-treated) = 9.8 × 10-19, P(aparasitemic) = 3.8 × 10-20. Independent samples t-test for the comparison between 
malaria-treated and aparasitemic individuals for the indicated age groups, *P = 0.02, †P = 0.05, ‡P = 0.03, ¶P = 0.11.
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Table 3: Univariate analysis of variance for %C3b-positive red cells as dependent variable
Unadjusted Adjusted
Groups Independent 
Variables
FB   (SE) 95% CI of B η2pP F B   (SE) 95% CI of B η2pP
All Age Groups 
(months)
21.8 -- -- 0.245 5.9 × 10-19 11.6 -- -- 0.149 2.5 × 10-10
N = 342 0 to ≤ 6 -- 4.13 (2.53) -0.85 to 9.10 0.008 0.10 -- 3.29 (2.45) -1.38 to 8.29 0.006 0.18
>6 to ≤ 36 -- 15.08 (1.75) 11.63 to 18.53 0.180 3.1 × 10-16 -- 11.61 (1.81) 8.05 to 15.18 0.111 1.8 × 10-10
>36 to ≤ 72 -- 9.17 (2.28) 4.68 to 13.66 0.046 7.3 × 10-5 -- 5.99 (2.30) 1.48 to 10.51 0.020 0.01
>72 to ≤ 144 -- 7.64 (2.33) 3.05 to 12.23 0.031 1.2 × 10-3 -- 4.61 (2.36) -0.03 to 9.24 0.011 0.07
>144 to ≤ 288 -- -1.64 (2.72) -7.00 to 3.72 0.001 0.55 -- -1.38 (2.68) -6.64 to 3.88 0.001 0.54
>288 to ≤ 540* -- -- -- -- -- -- -- -- -- --
CR1 46.1 -0.026 (0.004) -0.034 to -0.019 0.119 5.1 × 10-11 3.2 -0.008 (0.004) -0.016 to 0.001 0.010 0.07
CD55 35.3 -0.007 (0.001) -0.009 to -0.004 0.094 7.0 × 10-9 5.5 -0.003 (0.001) -4.8 × 10-3 to -0.4 × 10-
3
0.016 0.02
Malaria Negative† 17.8 -5.7 (1.4) -8.4 to -3.1 0.050 3.2 × 10-5 6.4 -3.34 (1.32) -5.93 to -0.74 0.019 0.01
Parasite Density 8.8 1.9 × 10-4 (0.6 × 10-4)0 . 6  ×  1 0 -4 to 3.2 × 10-4 0.025 3.2 × 10-3 0.5 4.1 × 10-5 (5.9 × 10-5) -0.8 × 10-4 to 1.6 × 10-4 0.001 0.49
ICBC 12.9 -0.358 (0.100) -0.554 to -0.162 0.037 3.8 × 10-4 2.0 -0.130 (0.092) -0.311 to 0.050 0.006 0.16
Malaria-treated Age Groups 
(months)
12.7 -- -- 0.306 3.2 × 10-10 9.0 -- -- 0.244 1.8 × 10-7
N = 150 0 to ≤ 6 -- 12.36 (6.06) 0.38 to 24.35 0.028 0.04 -- 10.08 (6.38) -2.53 to 22.68 0.018 0.12
>6 to ≤ 36 -- 21.48 (3.88) 13.81 to 29.15 0.175 1.4 × 10-7 -- 20.00 (4.13) 11.83 to 28.18 0.143 3.4 × 10-6
>36 to ≤ 72 -- 10.68 (4.28) 2.23 to 19.13 0.042 0.01 -- 10.01 (4.42) 1.28 to 18.73 0.035 0.03
>72 to ≤ 144 -- 9.49 (4.28) 1.04 to 17.94 0.033 0.02 -- 8.25 (4.43) -0.51 to 17.00 0.024 0.07
>144 to ≤ 288 -- -0.78 (5.22) -11.11 to 9.53 1.6 × 10-4 0.88 -- -0.69 (5.26) -11.10 to 9.72 1.2 × 10-4 0.90
>288 to ≤ 540* -- -- -- -- -- -- -- -- --
CR1 13.7 -0.030 (0.008) -0.046 to -0.014 0.085 3.0 × 10-4 3.0 -0.015 (0.009) -.032 to 0.002 0.021 0.09
CD55 7.2 -0.005 (0.002) -0.009 to -0.001 0.047 7.9 × 10-3 0.01 2.5 × 10-4 (21.1 × 10-4) -0.004 to 0.004 1.0 × 10-4 0.91
Parasite Density 2.6 1.2 × 10-4 (0.8 × 10-4) -0.3 × 10-4 to 2.7 × 10-4 0.017 0.11 0.1 -1.9 × 10-5 (6.8 × 10-5) -1.5 × 10-4 to 1.1 × 10-4 0.001 0.78
ICBC 0.2 -0.069 (0.171) -0.408 to 0.269 0.001 0.69 0.3 0.085 (0.155) -0.222 to 0.392 0.002 0.59
Malaria Negative Age Groups 
(months)
9.9 -- -- 0.210 2.2 × 10-8 4.8 -- -- 0.116 6.3 × 10-5
N = 192 0 to ≤ 6 -- 2.07 (2.50) -2.87 to 7.00 0.004 0.41 -- 1.76 (2.35) -2.93 to 6.34 0.003 0.47
>6 to ≤ 36 -- 10.80 (1.84) 7.17 to 14.43 0.156 2.0 × 10-8 -- 7.93 (1.82) 4.71 to 11.78 0.094 7.9 × 10-6
>36 to ≤ 72 -- 9.23 (2.95) 3.41 to 15.06 0.050 0.002 -- 7.76 (2.78) 2.49 to 13.43 0.041 4.6 × 10-3
>72 to ≤ 144 -- 7.09 (3.21) 0.75 to 13.43 0.025 0.03 -- 4.66 (3.05) -1.44 to 10.60 0.013 0.13
>144 to ≤ 288 -- -1.42 (3.03) -7.39 to 4.56 0.001 0.64 -- 0.33 (2.91) -5.83 to 5.45 7.0 × 10-5 0.95
>288 to ≤ 540* -- -- -- -- -- -- -- -- -- --
CR1 29.4 -0.022 (0.004) -0.030 to -0.014 0.134 1.8 × 10-7 1.0 -0.004 (0.005) -0.014 to 0.005 0.005 0.33
CD55 27.0 -0.006 (0.001) -0.009 to -0.004 0.124 5.2 × 10-7 8.6 -0.004 (0.001) -0.006 to -0.001 0.045 3.8 × 10-3
ICBC 26.9 -0.564 (0.109) -0.779 to -0.350 0.124 5.4 × 10-7 9.0 -0.326 (0.109) -0.540 to -0.111 0.047 3.1 × 10-3
*B for this group set to '0' as reference.
†B for malaria-treated group was set to '0' as reference.
η2p = Partial Eta squared or coefficient of non-linear correlation.
ICBC = IC binding capacity.B
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Table 4: Univariate analysis of variance for hemoglobin as dependent variable
Unadjusted Adjusted
Groups Independent 
Variables
FB   (SE) 95% CI of B η2pP F B   (SE) 95% CI of B η2pP
All Age Groups 
(months)
48.5 -- -- 0.419 9.6 × 10-38 26.5 -- -- 0.287 1.5 × 10-22
N = 342 0 to ≤ 6 -- -1.94 (0.36) -2.64 to -1.23 0.080 1.2 × 10-7 -- -1.86 (0.34) -2.54 to -1.18 0.080 1.5 × 10-7
>6 to ≤ 36 -- -3.13 (0.25) -3.62 to -2.64 0.321 4.7 × 10-30 -- -2.59 (0.27) -3.13 to -2.07 0.219 7.3 × 10-19
>36 to ≤ 72 -- -1.94 (0.32) -2.58 to -1.31 0.097 5.0 × 10-9 -- -1.72 (0.33) -2.36 to -1.08 0.078 2.3 × 10-7
>72 to ≤ 144 -- -0.54 (0.33) -1.19 to 0.11 0.008 0.10 -- -0.35 (0.33) -1.01 to 0.30 0.003 0.29
>144 to ≤ 288 -- 0.20 (0.39) -0.55 to 0.96 0.001 0.60 -- -0.11 (0.38) -0.85 to 0.63 2.6 × 10-4 0.77
>288 to ≤ 540* -- -- -- -- -- -- -- -- -- --
CR1 63.3 0.005 (0.001) 0.004 to 0.006 0.157 2.7 × 10-14 20.4 0.003 (0.001) 0.002 to 0.004 0.058 8.7 × 10-6
CD55 10.3 5.9 × 10-4 (1.8 × 10-4)2 . 3  ×  1 0 -4 to 9.5 × 10-4 0.029 1.5 × 10-3 5.9 -3.8 × 10-4 (1.6 × 10-4) -6.9 × 10-4 to -0.7 × 10-4 0.018 0.02
Malaria Status† 1.2 0.246 (0.224) -0.195 to 0.686 0.004 0.27 0.3 -0.103 (0.187) -0.471 to 0.265 0.001 0.58
Parasite Density 4.9 -2.3 × 10-5 (1.0 × 10-5) -4.3 × 10-5 to -0.3 × 10-5 0.014 0.03 1.1 × 10-5 0.3 × 10-7 (82.7 × 10-7) -1.6 × 10-5 to 1.6 × 10-5 3.5 × 10-8 1.00
ICBC 11.9 0.056 (0.016) 0.024 to 0.087 0.034 6.3 × 10-4 0.02 0.002 (0.013) -0.024 to 0.027 6.0 × 10-5 0.89
%C3b-positive 
Red Cells
77.6 -0.070 (0.008) -0.085 to -0.054 0.186 6.6 × 10-17 10.5 -0.025 (0.008) -0.040 to -0.010 0.031 1.3 × 10-3
Malaria-treated Age Groups
(months)
27.2 -- -- 0.486 2.7 × 10-19 15.3 -- -- 0.355 6.0 × 10-12
N = 150 0 to ≤ 6 -- -3.09 (0.68) -4.42 to -1.75 0.127 1.1 × 10-5 -- -2.74 (0.68) -4.09 to -1.39 0.103 1.0 × 10-4
>6 to ≤ 36 -- -2.98 (0.43) -3.83 to -2.12 0.247 1.7 × 10-10 -- -2.54 (0.48) -3.48 to -1.60 0.170 3.7 × 10-7
>36 to ≤ 72 -- -1.53 (0.48) -2.47 to -0.59 0.067 1.7 × 10-3 -- -1.45 (0.48) -2.39 to -0.50 0.062 2.9 × 10-3
>72 to ≤ 144 -- -0.12 (0.48) -1.06 to 0.82 4.5 × 10-4 0.80 -- -0.03 (0.48) -0.91 to 0.97 3.0 × 10-5 0.95
>144 to ≤ 288 -- -0.31 (0.58) -1.46 to 0.85 0.002 0.60 -- -0.46 (0.56) -1.56 to 0.65 0.005 0.41
>288 to ≤ 540* -- -- -- -- -- -- -- -- --
CR1 28.2 0.005 (0.001) 0.003 to 0.007 0.160 3.9 × 10-7 13.0 0.003 (0.001) 0.002 to 0.005 0.085 4.4 × 10-4
CD55 7.2 7.0 × 10-4 (2.6 × 10-4)1 . 9  ×  1 0 -4 to 12.2 × 10-4 0.047 8.1 × 10-3 2.0 -3.2 × 10-4 (2.2 × 10-4) -7.6 × 10-4 to 1.3 × 10-4 0.014 0.16
Parasite Density 5.0 -2.2 × 10-5 (1.0 × 10-5) -4.1 × 10-5 to -0.3 × 10-5 0.033 0.03 0.002 3.2 × 10-7 (0.7 × 10-7) -1.4 × 10-5 to 1.5 × 10-5 1.4 × 10-5 0.96
ICBC 3.2 0.039 (0.022) 0.004 to 0.083 0.021 0.08 0.3 0.008 (0.017) -0.024 to 0.041 0.002 0.61
%C3b-positive 
Red Cells
34.9 -0.057 (0.010) -0.075 to -0.038 0.191 2.3 × 10-8 1.9 -0.012 (0.009) -0.030 to 0.005 0.014 0.17
Malaria 
Negative
Age Groups 
(months)
26.4 -- -- 0.415 4.4 × 10-20 14.4 -- -- 0.284 7.0 × 10-12
N = 192 0 to ≤ 6 -- -1.65 (0.44) -2.51 to -0.79 0.072 2.1 × 10-4 -- -1.63 (0.42) -2.46 to -0.80 0.077 1.4 × 10-4
>6 to ≤ 36 -- -3.15 (0.32) -3.78 to -2.52 0.342 1.2 × 10-18 -- -2.62 (0.34) -3.30 to -1.95 0.246 8.0 × 10-13
>36 to ≤ 72 -- -2.41 (0.51) -3.43 to -1.40 0.106 5.2 × 10-6 -- -1.97 (0.51) -2.97 to -0.97 0.077 1.4 × 10-4
>72 to ≤ 144 -- -1.15 (0.56) -2.25 to -0.04 0.022 0.04 -- -0.98 (0.55) -2.06 to 0.10 0.017 0.07
>144 to ≤ 288 -- 0.65 (0.53) -0.39 to 1.69 0.008 0.22 -- 0.31 (0.52) -0.71 to 1.33 0.002 0.55
>288 to ≤ 540* -- -- -- -- -- -- -- -- -- --
CR1 33.9 0.005 (0.001) 0.003 to 0.006 0.151 2.4 × 10-8 7.6 0.002 (0.001) 0.001 to 0.004 0.040 0.01
CD55 3.5 4.9 × 10-4 (2.6 × 10-4) -0.2 × 10-4 to 10.0 × 10-
4
0.018 0.06 5.0 -4.9 × 10-4 (2.2 × 10-4) -9.3 × 10-4 to -0.6 × 10-4 0.027 0.03
ICBC 8.6 0.068 (0.023) 0.022 to 0.113 0.043 3.7 × 10-3 0.4 -0.012 (0.020) -0.052 to 0.027 0.002 0.53
%C3b-positive 
Red Cells
46.3 -0.090 (0.013) -0.116 to -0.064 0.196 1.3 × 10-10 10.7 -0.043 (0.013) -0.069 to -0.017 0.056 1.3 × 10-3
*B for this group set to '0' as reference.
†B for malaria-treated group was set to '0' as reference.
η2p = Partial Eta squared or coefficient of non-linear correlation.
ICBC = IC binding capacity.BMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
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Discussion
Severe anemia due to P. falciparum occurs principally in
young children and is most common in areas of intense
malaria transmission [4,5,38]. Cerebral malaria, on the
other hand, occurs in older children and adults in areas of
low transmission, and the incidence can increase with age
[5,39]. Identifying the mechanisms underlying these dis-
parities in age-related susceptibilities is critical to under-
standing the pathogenesis of severe malaria. We
previously reported that the levels of red cell complement
regulatory proteins CR1 and CD55, which protect red cells
from autologous complement attack, vary with age, being
high in neonates, decreasing after 6 months and increas-
ing some time after into adulthood [40]. This pattern of
expression is independent of malaria infection and of the
ethnic background of the population [41]. Our primary
objective was to determine whether low levels of red cell
complement regulatory proteins are associated with
increased C3b deposition on red cells and, secondarily,
with low hemoglobin in a malaria-endemic area. Because
we have previously observed that individuals with malaria
have lower levels of red cell complement regulatory pro-
teins [13,42], we controlled for the effect of parasitemia
on this parameter by administering anti-malarial treat-
ment to malaria-positive participants and collecting the
blood sample only when they were smear negative.
Restrictions on the amount of blood that can be drawn
from very young children limited the number of blood
draws within our time frame to one.
The relationship between red cell C3b and red cell com-
plement regulatory protein expression seemed complex
(Figures 1 and 2a). Red cell CR1 appeared to be more age-
dependent than CD55 or the IC binding capacity. The
peak of %C3b-positive red cells coincided with the nadir
of red cell CR1 (Figures 1b and 2a) suggesting a stronger
relationship between C3b and CR1 than between C3b
and CD55 or the IC binding capacity. However, in the
overall ANOVA model (Table 3) CD55 made a stronger
contribution. This could be explained by the fact that
CD55 seemed to be more important in preventing C3b
deposition in malaria-negative individuals, who were
more numerous in the study group. Although not statisti-
cally significant (P  = 0.09), CR1 appeared to be more
important than CD55 in protecting red cells from C3b
deposition during malaria infection (Table 3). These
observations point to distinct mechanisms of action
between CR1 and CD55. Since studies have shown that
there is active complement activation during malaria
infection [9,43], our observations suggest that CR1 is
more effective than CD55 at preventing C3b deposition
on cells.
The presence of parasitemia seemed to be a more impor-
tant contributor to C3b deposition than the degree of par-
asitemia. This is somewhat surprising since although
parasite density peaked at an earlier age than parasite
prevalence (Figures 2b and 2c), both parameters peaked
within the same age range as the peak for %C3b-positive
red cells (Figure 2a). However, malaria-treated individuals
≤ 24 months of age tended to have higher %C3b-positive
red cells than malaria-negative individuals, regardless of
the level of parasitemia (Figures 2c and 3a), suggesting
that the level of parasitemia is less important. Although
we cannot exclude the possibility that malaria treatment
may have exacerbated C3b deposition on red cells, and
thus biased our results, we have observed C3b deposition
on red cells of acutely infected children prior to treatment
in other studies [44]. Thus, the C3b deposition on red
cells of children who were treated for malaria is likely
residual from the original infection.
It is interesting that increased C3b deposition was also
seen on red cells of children with low red cell complement
regulatory protein but without malaria infection, suggest-
ing that there is a defect in the normal regulatory mecha-
nisms during this age that prevent spontaneous
complement activation. Alternatively, C3b on apara-
sitemic individuals may have been residual from recent
previous malaria infections or infections with other
agents. It is also possible that some or many of these indi-
viduals have levels of parasitemia below the limit of detec-
tion of microscopy.
The question of whether parasite prevalence or parasite
density is a contributor to uninfected red cell destruction
has important ramifications for the understanding of the
pathogenesis of severe anemia during malaria. Current
belief is that natural acquired immunity does not sterilize
but suppresses the level of parasitemia and, therefore, par-
asite density is a reflection of the level of immunity [45].
Hence, if malaria prevalence is a function of exposure
only, with no role for acquired immunity, at least early
on, this would suggest that the age specificity of severe
anemia due to malaria is being driven solely by the phys-
iologic changes in the ability of children to regulate com-
plement activation, namely age-related declines in red cell
complement regulators. In this case, one would predict
that there would be no relationship between severe ane-
mia and the level of parasitemia, as we have found in pre-
vious studies [13,46,47]. On the other hand, if changes in
parasite prevalence are being driven by acquisition and
loss of immunity then obviously immunity would play a
role, but in this case one would expect parasite density to
be an important factor as well.
The most important variables that influenced the hemo-
globin level in this study were age, red cell CR1, %C3b-
positive red cells, and red cell CD55 (Table 4). Interest-
ingly, the effect of CD55 on hemoglobin was always neg-BMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
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ative. The most likely reason is because as CD55 decreased
to a nadir at age >24 to ≤ 36 months the hemoglobin
increased (Figures 2a and 2c). These observations are con-
sistent with the role of C3b in the destruction of red cells
and with the more important role of CR1 over CD55 in
the protection of red cells from complement activation. In
the analysis of samples from malaria-treated individuals,
only CR1 and age made significant contributions. The
absence of %C3b as an important factor here is surprising
given the high proportion of C3b-positive red cells associ-
ated with low hemoglobin in malaria-treated individuals
(Figures 3a and 3d), and suggests that even in the setting
of high C3b deposition high red cell CR1 may be protec-
tive. The failure of parasite density and malaria status to
make significant contributions to the hemoglobin level
probably reflects the fact that malaria treatment elimi-
nated any difference in the hemoglobin level between
malaria-treated and aparasitemic participants (data not
shown). Therefore, the model presented here is free of the
direct effects of the parasite on the destruction of red cells
but retains the indirect effects of complement-mediated
mechanisms.
The two ANOVA models (Tables 3 and 4) suggest the
importance of age as the strongest factor determining C3b
deposition on red cells and the hemoglobin level. The
implication of this finding for complement activation is
that quite possibly there still remain to be identified other
age-related factors that regulate complement activation
and deposition on red cells. The relationship between age
and hemoglobin level is probably multifactorial and
likely includes factors such as diet, and iron deficiency as
well as the contribution of age effects on complement reg-
ulation.
Our data suggest that children >6 to ≤ 36 months of age
who develop malaria are at high risk of uninfected red cell
destruction due to ineffective complement regulation.
They have relatively low red cell CR1 that may be insuffi-
cient to control complement activation on cell surfaces.
On the other side of this equation is the contribution of
macrophage activation, which should also be considered.
Macrophages can be activated by the malaria pigment
hemozoin as well as by malaria GPI, leading to increased
production of pro-inflammatory cytokines which can
upregulate the expression of complement receptors lead-
ing to phagocytosis [48-50]. In addition, several studies
have documented an inverse relationship between TNF-α
production, in response to malaria infection, and age
[51,52]. Thus, in addition to high red cell C3b, para-
sitemic children ≤ 24 months of age may have overstimu-
lated macrophages, making their red cells more
susceptible to erythrophagocytosis and severe anemia.
Conclusion
These results suggest that increasing malaria prevalence
among children >6 to ≤ 36 months of age in western
Kenya together with low red cell CR1 and CD55 levels
result in increased C3b deposition on red cells leading to
increased red cell destruction by phagocytosis. The strong
contribution of age to C3b deposition suggests that there
are still additional unidentified age-related factors that
increase the susceptibility to C3b deposition on red cells
and red cell destruction.
Abbreviations
ANCOVA: analysis of covariance; ANOVA: analysis of var-
iance; DAF: decay accelerating factor; EDTA: ethylenedi-
aminetetraacetic acid; FITC: fluorescein isothiocyanate;
GPI: glycosyl-phosphatidyl-inositol; IC: immune com-
plex; MFI: median fluorescence intensity; PBS: phosphate
buffered saline.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
COO carried out flow cytometry to measure the red cell
C3b. WO supervised the recruitment and evaluation of
the study participants. CA supervised the measurement of
clinical laboratory parameters. MMO carried out flow
cytometry to measure red cell CR1, CD55, and IC binding
capacity. JAS and WO designed the study and wrote the
protocol. COO and JAS drafted the manuscript which was
reviewed and approved by all.
Acknowledgements
We would like to thank the participants for their willingness to contribute 
to this research endeavor. We are indebted to our dedicated staff of clini-
cians, nurses, drivers and field workers who made this study possible. In 
particular, we thank Stacey Gondi for serving as research coordinator. Mr. 
Meng Shi is thanked for statistical advice. This work is published with the 
permission of the Office of the Director, the Kenya Medical Research Insti-
tute.
This work was supported in part by the US Army Medical Research and 
Materiel Command and by a grant from the National Heart Lung and Blood 
Institute (R01 HL 7502), José A. Stoute PI. Walter Otieno was supported 
by a training grant from the Fogarty International Center (1 D43 
TW06239).
"The views of the authors do not purport to reflect the position of the 
Department of the Army or the Department of Defense. The U.S. Govern-
ment has the right to retain a nonexclusive, royalty-free license in and to 
any copyright covering this paper."
References
1. Breman JG: The ears of the hippopotamus: manifestations,
determinants, and estimates of the malaria burden.  Am J Trop
Med Hyg 2001, 64:1-11.
2. Snow RW, Bastos dAI, Lowe BS, Kabiru EW, Nevill CG, Mwankusye
S, Kassiga G, Marsh K, Teuscher T: Severe childhood malaria inBMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
Page 13 of 14
(page number not for citation purposes)
two areas of markedly different falciparum transmission in
east Africa.  Acta Trop 1994, 57:289-300.
3. Imbert P, Sartelet I, Rogier C, Ka S, Baujat G, Candito D: Severe
malaria among children in a low seasonal transmission area,
Dakar, Senegal: influence of age on clinical presentation.
Trans R Soc Trop Med Hyg 1997, 91:22-24.
4. Modiano D, Sirima BS, Sawadogo A, Sanou I, Pare J, Konate A, Pagnoni
F: Severe malaria in Burkina Faso: influence of age and trans-
mission level on clinical presentation.  Am J Trop Med Hyg 1998,
59:539-542.
5. Marsh K, Snow RW: Malaria transmission and morbidity.  Par-
assitologia 1999, 41:241-246.
6. Looareesuwan S, Ho M, Wattanagoon Y, White NJ, Warrell DA, Bun-
nag D, Harinasuta T, Wyler DJ: Dynamic alteration in splenic
function during acute falciparum malaria.  N Engl J Med 1987,
317:675-679.
7. Camacho LH, Gordeuk VR, Wilairatana P, Pootrakul P, Brittenham
GM, Looareesuwan S: The course of anaemia after the treat-
ment of acute, falciparum malaria.  Ann Trop Med Parasitol 1998,
92:525-537.
8. Jakeman GN, Saul A, Hogarth WL, Collins WE: Anaemia of acute
malaria infections in non-immune patients primarily results
from destruction of uninfected erythrocytes.  Parasitology 1999,
119(Pt 2):127-133.
9. Jhaveri KN, Ghosh K, Mohanty D, Parmar BD, Surati RR, Camoens
HM, Joshi SH, Iyer YS, Desai A, Badakere SS: Autoantibodies,
immunoglobulins, complement and circulating immune
complexes in acute malaria.  Natl Med J India 1997, 10:5-7.
10. Roestenberg M, McCall M, Mollnes TE, van DM, Sprong T, Klasen I,
Hermsen CC, Sauerwein RW, van dV: Complement activation in
experimental human malaria infection.  Trans R Soc Trop Med
Hyg 2007, 101:643-649.
11. Freedman J: Membrane-bound immunoglobulins and comple-
ment components on young and old red cells.  Transfusion
1984, 24:477-481.
12. Goka BQ, Kwarko H, Kurtzhals JA, Gyan B, Ofori-Adjei E, Ohene SA,
Hviid L, Akanmori BD, Neequaye J: Complement binding to
erythrocytes is associated with macrophage activation and
reduced haemoglobin in Plasmodium falciparum malaria.
Trans R Soc Trop Med Hyg 2001, 95:545-549.
13. Waitumbi JN, Opollo MO, Muga RO, Misore AO, Stoute JA: Red cell
surface changes and erythrophagocytosis in children with
severe  Plasmodium falciparum anemia.  Blood 2000,
95:1481-1486.
14. Weiss L, Fischer E, Haeffner-Cavaillon N, Jouvin MH, Appay MD, Bari-
ety J, Kazatchkine M: The human C3b receptor (CR1).  Adv Neph-
rol Necker Hosp 1989, 18:249-269.
15. Yazdanbakhsh K: Review: complement receptor 1 therapeutics
for prevention of immune hemolysis.  Immunohematology 2005,
21(3):109-118.
16. Madi N, Paccaud JP, Steiger G, Schifferli JA: Immune complex
binding efficiency of erythrocyte complement receptor 1
(CR1).  Clin Exp Immunol 1991, 84:9-15.
17. Reinagel ML, Gezen M, Ferguson PJ, Kuhn S, Martin EN, Taylor RP:
The primate erythrocyte complement receptor (CR1) as a
privileged site: binding of immunoglobulin G to erythrocyte
CR1 does not target erythrocytes for phagocytosis.  Blood
1997, 89:1068-1077.
18. Nicholson-Weller A: Decay accelerating factor (CD55).  Curr
Top Microbiol Immunol 1992, 178:7-30.
19. Miwa T, Song WC: Membrane complement regulatory pro-
teins: insight from animal studies and relevance to human
diseases.  Int Immunopharmacol 2001, 1:445-459.
20. Parker CJ: Regulation of complement by membrane proteins:
an overview.  Curr Top Microbiol Immunol 1992, 178:1-6.
21. Mibei EK, Orago AS, Stoute JA: Immune complex levels in chil-
dren with severe Plasmodium falciparum malaria.  Am J Trop
Med Hyg 2005, 72:593-599.
22. Owuor BO, Odhiambo CO, Otieno WO, Adhiambo C, Makawiti DW,
Stoute JA: Reduced immune complex binding capacity and
increased complement susceptibility of red cells from chil-
dren with severe malaria-associated anemia.  Mol Med 2008,
14:89-97.
23. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
24. Stoute JA: Complement-regulatory proteins in severe
malaria: too little or too much of a good thing?  Trends Parasitol
2005, 21:218-223.
25. Beier JC, Perkins PV, Onyango FK, Gargan TP, Oster CN, Whitmire
RE, Koech DK, Roberts CR: Characterization of malaria trans-
mission by Anopheles (Diptera: Culicidae) in western Kenya
in preparation for malaria vaccine trials.  J Med Entomol 1990,
27:570-577.
26. Mibei EK, Orago AS, Stoute JA: Immune complex levels in chil-
dren with severe Plasmodium falciparum malaria.  Am J Trop
Med Hyg 2005, 72:593-599.
27. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
28. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
29. Pascual M, Danielsson C, Steiger G, Schifferli JA: Proteolytic cleav-
age of CR1 on human erythrocytes in vivo: evidence for
enhanced cleavage in AIDS.  Eur J Immunol 1994, 24:702-708.
30. Takemura S, Deguchi M, Ueda M, Yoshida N, Kato H, Yoshikawa T,
Sugino S, Kondo M: C3b receptor (CR1) on erythrocytes in var-
ious diseases.  Immunol Lett 1984, 7:325-328.
31. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR,
Taylor RP, Myones BL, Lachmann PJ: Disease-associated loss of
erythrocyte complement receptors (CR1, C3b receptors) in
patients with systemic lupus erythematosus and other dis-
eases involving autoantibodies and/or complement activa-
tion.  J Immunol 1985, 135:2005-2014.
32. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the
treatment of uncomplicated falciparum malaria.  Expert Opin
Pharmacother 2007, 8:75-94.
33. Cockburn IA, Donvito B, Cohen JH, Rowe JA: A simple method
for accurate quantification of complement receptor 1 on
erythrocytes preserved by fixing or freezing.  J Immunol Meth-
ods 2002, 271:59-64.
34. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
35. Schwartz A, Ottinger J, Wallace E, Poon R, Fernandez-Repollet E:
Quantitative determination of antibody binding capacity
(ABC) by flow cytometry.  Eur J Histochem 1994, 38(Suppl
1):13-20.
36. Overton WR: Modified histogram subtraction technique for
analysis of flow cytometry data.  Cytometry 1988, 9:619-626.
37. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
38. Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer
A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta
S, Marsh K: Relation between severe malaria morbidity in chil-
dren and level of Plasmodium falciparum transmission in
Africa.  Lancet 1997, 349:1650-1654.
39. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ:
The epidemiology of severe malaria in an area of low trans-
mission in Thailand.  Trans R Soc Trop Med Hyg 1997, 91:256-262.
40. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
41. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
42. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
43. Roestenberg M, McCall M, Mollnes TE, van DM, Sprong T, Klasen I,
Hermsen CC, Sauerwein RW, van dV: Complement activation inPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2008, 6:23 http://www.biomedcentral.com/1741-7015/6/23
Page 14 of 14
(page number not for citation purposes)
experimental human malaria infection.  Trans R Soc Trop Med
Hyg 2007, 101:643-649.
44. Owuor BO, Odhiambo CO, Otieno WO, Adhiambo C, Makawiti
DW, Stoute JA: Reduced immune complex binding capacity
and increased complement susceptibility of red cells from
children with severe malaria-associated anemia.  Mol Med
2008, 14:89-97.
45. Rogier C, Tall A, Diagne N, Fontenille D, Spiegel A, Trape JF: Plasmo-
dium falciparum clinical malaria: lessons from longitudinal
studies in Senegal.  Parassitologia 1999, 41:255-259.
46. Owuor BO, Odhiambo CO, Otieno WO, Adhiambo C, Makawiti
DW, Stoute JA: Reduced immune complex binding capacity
and increased complement susceptibility of red cells from
children with severe malaria-associated anemia.  Mol Med
2008, 14:89-97.
47. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA: Age-
related changes in red blood cell complement regulatory
proteins and susceptibility to severe malaria.  J Infect Dis 2004,
190:1183-1191.
48. Jaramillo M, Godbout M, Olivier M: Hemozoin induces macro-
phage chemokine expression through oxidative stress-
dependent and -independent mechanisms.  J Immunol 2005,
174:475-484.
49. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S,
Woods AS, Gowda DC: Induction of proinflammatory
responses in macrophages by the glycosylphosphatidylinosi-
tols of Plasmodium falciparum: cell signaling receptors, glyco-
sylphosphatidylinositol (GPI) structural requirement, and
regulation of GPI activity.  J Biol Chem 2005, 280:8606-8616.
50. Kitagawa S, Yuo A, Yagisawa M, Azuma E, Yoshida M, Furukawa Y,
Takahashi M, Masuyama J, Takaku F: Activation of human mono-
cyte functions by tumor necrosis factor: rapid priming for
enhanced release of superoxide and erythrophagocytosis,
but no direct triggering of superoxide release.  Exp Hematol
1996, 24:559-567.
51. Mshana RN, Boulandi J, Mshana NM, Mayombo J, Mendome G:
Cytokines in the pathogenesis of malaria: levels of IL-I beta,
IL-4, IL- 6, TNF-alpha and IFN-gamma in plasma of healthy
individuals and malaria patients in a holoendemic area.  J Clin
Lab Immunol 1991, 34:131-139.
52. Nyakundi JN, Warn P, Newton C, Mumo J, Jephthah-Ochola J:
Serum tumour necrosis factor in children suffering from
Plasmodium falciparum infection in Kilifi District, Kenya.  Trans
R Soc Trop Med Hyg 1994, 88:667-670.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/6/23/prepub